פלולן אפופרוסטנול 500 מקג לעירוי
glaxo smith kline (israel) ltd - epoprostenol as sodium - אבקה להכנת תמיסה לאינפוזיה - epoprostenol as sodium 0.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.
זובירקס iv
glaxo smith kline (israel) ltd - aciclovir - אבקה להכנת תמיסה לאינפוזיה - aciclovir 250 mg/vial - aciclovir - aciclovir - for the treatment of herpes simplex infections and severe initial genital herpes in the non immunocompromised. for the prophylaxis of herpes simplex infections in immune-compromised patients. in the treatment of varicella zoster infections. for herpes simplex encephalitis. for the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.
אינפנריקס אי.פי.וי. איץ'.אי.בי
glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens
סקייריזי 600 מג
abbvie biopharmaceuticals ltd, israel - risankizumab - תרכיז להכנת תמיסה לאינפוזיה - risankizumab 60 mg/ml - risankizumab
ריספרידון טבע 25 מג
teva israel ltd - risperidone - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - risperidone 25 mg/vial - risperidone
ריספרידון טבע 37.5 מג
teva israel ltd - risperidone - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - risperidone 37.5 mg/vial - risperidone
ריספרידון טבע 50 מג
teva israel ltd - risperidone - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - risperidone 50 mg/vial - risperidone
נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 2 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 5 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.